BlueCrest Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

BlueCrest Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-14,967	Closed	-$1.49M	–	473
2019 Q3	$1.49M	Buy	14,967 +9,318	+165%	+$975K	0.1%	145
2019 Q2	$616K	Buy	+5,649	New	+$601K	0.04%	194
2019 Q1	–	Sell	-26,257	Closed	-$2.53M	–	1253
2018 Q4	$2.53M	Buy	26,257 +15,060	+135%	+$1.6M	0.13%	118
2018 Q3	$1.36M	Sell	11,197 -65,015	-85%	-$7.66M	0.04%	350
2018 Q2	$8.37M	Buy	76,212 +64,237	+536%	+$6.87M	0.22%	97
2018 Q1	$1.28M	Sell	11,975 -92,804	-89%	-$10.3M	0.04%	416
2017 Q4	$11.2M	Sell	104,779 -144,296	-58%	-$15.4M	0.3%	59
2017 Q3	$27.7M	Buy	249,075 +182,997	+277%	+$19.6M	1.13%	9
2017 Q2	$6.83M	Buy	+66,078	New	+$6.51M	0.26%	111
2017 Q1	–	Sell	-92,799	Closed	-$8.21M	–	848
2016 Q4	$8.21M	Buy	+92,799	New	+$8.45M	0.45%	53
2016 Q3	–	Sell	-59,388	Closed	-$5.09M	–	859
2016 Q2	$5.09M	Buy	+59,388	New	+$5.33M	0.21%	111
2015 Q4	–	Sell	-53,358	Closed	-$5.39M	–	1071
2015 Q3	$5.39M	Buy	+53,358	New	+$6.4M	0.18%	101

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

BlueCrest Capital Management's IBB Position: Q4 2019 in Review

BlueCrest Capital Management sold out of iShares Biotechnology ETF (IBB) in Q4 2019, closing a stake of 14,967 shares — an estimated $1.49M sold.

BlueCrest Capital Management first reported a position in IBB in Q3 2015 and held it in 12 quarters. The position peaked at $27.7M in Q3 2017. 710 funds tracked by Wall St. Rank hold IBB as of Q4 2019.

BlueCrest Capital Management reported no remaining iShares Biotechnology ETF position as of Q4 2019 after selling out during the quarter.
BlueCrest Capital Management sold 14,967 iShares Biotechnology ETF shares in Q4 2019, an estimated $1.49M.
BlueCrest Capital Management first reported a position in iShares Biotechnology ETF in Q3 2015 and held it in 12 quarters.
BlueCrest Capital Management's iShares Biotechnology ETF position peaked at $27.7M in Q3 2017.
710 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2019.

Based on BlueCrest Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.